Delivery Order SPE2DB22D2206-SPE2DB25FEH03

Award Date 11/18/24
Potential Completion Date 11/19/24
Potential Value $4.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Cyclosporine 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, under a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military...
This federal contract award is for the delivery of Cyclosporine 0.05% eye emulsion for the Defense Logistics Agency (DLA). The firm-fixed-price delivery order, valued at $2,802.97, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of January 9, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award is for the delivery of Cyclosporine 0.05% eye emulsion 60s, a specialized pharmaceutical product, to the Defense Logistics Agency (DLA). The $7,546.26 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of October 17, 2023. AmerisourceBergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,514.95 firm fixed-price delivery order is for the supply of CYCLOSPORINE 0.05% EYE EMULS 60S, a pharmaceutical product. The contract has an ultimate completion date of March 3, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support...
This federal contract award, valued at $1,157.52, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, which does not have a set-aside designation, is a delivery order for 4567237402 CYCLOSPORINE 0.05% EYE EMULS 30S. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which...
This federal contract award is for the delivery of Cyclosporine 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $8,064.14 firm fixed price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on July 17, 2024 with a completion date of July 18, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,527.92 firm fixed-price delivery order is for the supply of Cyclosporine 0.05% eye emulsion, a specialty pharmaceutical product. The contract has a completion date of November 1, 2024 and was awarded on October 31, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award is for the delivery of Cyclosporine 0.05% eye emulsion to support Defense Logistics Agency (DLA) Troop Support Medical operations. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., a major pharmaceutical distribution firm. The award, valued at $6,320.92, is a firm-fixed price delivery order contract with a completion date of January 26, 2024. This contract is not designated as a set-aside. Amerisourcebergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,427.76 firm fixed-price delivery order is for the supply of Cyclosporine 0.05% eye emulsion, with a completion date of December 15, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award is for the delivery of 4,558,549,115 units of Cyclosporine 0.05% eye emulsion in 60-count packages. The $27,929.37 firm fixed price contract was awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. AmerisourceBergen is a major pharmaceutical distribution company that holds a single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FEH03
    Delivery Order

This federal contract award is for the delivery of CYCLOSPORINE 0.05% EYE EMULS 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,430.12 Firm Fixed Price Delivery Order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This particular award has an ultimate completion date of November 19, 2024 and was not designated with any set-aside requirements, indicating open competition.

Generated 2/17/25, 9:44 PM